SCHEMBL3477555

SCHEMBL3477555

O=C(O)CCN1CCc2ccccc2C1

nearest known ligand 0.70

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HDAC3 O15379 2/20 0.70
HDAC1 Q13547 2/20 0.70
HDAC8 Q9BY41 2/20 0.70
NCOR2 Q9Y618 2/20 0.70
KDM4E B2RXH2 3/20 0.69
ALOX15 P16050 1/20 0.69
HTR7 P34969 6/20 0.67
HTR1A P08908 5/20 0.67
DRD2 P14416 5/20 0.67
DRD3 P35462 5/20 0.67
HTR2B P41595 5/20 0.67
HTR2A P28223 4/20 0.67
HRH1 P35367 4/20 0.67
SLC6A4 P31645 1/20 0.67
PRMT5 O14744 1/20 0.64
WDR77 Q9BQA1 1/20 0.64
HDAC2 Q92769 1/20 0.59
MEN1 O00255 2/20 0.59
KMT2A Q03164 2/20 0.59
L3MBTL1 Q9Y468 2/20 0.59

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8687907 0.90 HTR7 (0.76) HDAC3HDAC1HDAC8NCOR2KDM4E
Hydrochloric Acid SCHEMBL3887340 0.89 HTR7 (0.74) HDAC3HDAC1HDAC8NCOR2KDM4E
SCHEMBL17598257 0.89 HDAC3 (0.71) HDAC3HDAC1HDAC8NCOR2KDM4E
Hydrochloric Acid SCHEMBL6986394 0.86 KDM4E (0.54) HDAC3HDAC1HDAC8NCOR2KDM4E
SCHEMBL31093171 0.86 HTR1A (0.84) HDAC3HDAC1HDAC8NCOR2KDM4E
SCHEMBL3891857 0.85 HDAC3 (0.68) HDAC3HDAC1HDAC8NCOR2KDM4E
Hydrochloric Acid SCHEMBL4251907 0.84 HDAC3 (0.67) HDAC3HDAC1HDAC8NCOR2KDM4E
SCHEMBL3478431 0.83 ALDH1A1 (0.59) HDAC3HDAC1HDAC8NCOR2KDM4E
SCHEMBL14421980 0.81 DRD2 (0.51) HDAC3HDAC1HDAC8NCOR2KDM4E
SCHEMBL5546764 0.81 HDAC3 (0.68) HDAC3HDAC1HDAC8NCOR2KDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2364976-A1 S1P receptor modulating compounds and use thereof EPIX Pharmaceuticals, Inc. (US) 2011-09-14 EP disclosed
US-20110212940-A1 S1P Receptor Modulating Compounds and Use Thereof EPIX PHARMACEUTICALS, INC. (US) 2011-09-01 US disclosed
US-7919519-B2 1-(4-(5-Phenylbenzofuran-2-yl)benzyl)azetidine-3-carboxylic acids; anticarcinogenic, antiinflammatory, antiarthritic, antidiabetic agents; transplant rejection, autoimmune diseases, lupus, multiple sclerosis, psoriasis, inflammatory bowel disease, Chron's disease EPIX PHARMACEUTICALS INC. (US) 2011-04-05 US disclosed
US-20110059945-A1 S1P Receptor Modulating Compounds and Use Thereof EPIX PHARMACEUTICALS, INC. (US) 2011-03-10 US disclosed
US-7855193-B2 S1P receptor modulating compounds and use thereof EPIX PHARMACEUTICALS, INC. (US) 2010-12-21 US disclosed
WO-2010069949-A1 OXADIAZOLE FUSED HETEROCYCLIC DERIVATIVES USEFUL FOR THE TREATMENT OF MULTIPLE SCLEROSIS MERCK SERONO S.A. (CH) 2010-06-24 WO disclosed
US-20080064677-A9 S1P receptor modulating compounds and use thereof PREDIX PHARMACEUTICAL HOLDINGS 2008-03-13 US disclosed
US-20080027036-A1 S1P receptor modulating compounds and use thereof EPIX DELAWARE, INC. (US) 2008-01-31 US disclosed
WO-2007109334-A2 SIP RECEPTOR MODULATING COMPOUNDS AND USE THEREOF EPIX DELAWARE, INC. (US) 2007-09-27 WO disclosed
US-20070173487-A1 S1P receptor modulating compounds and use thereof PREDIX PHARMACEUTICAL HOLDINGS 2007-07-26 US disclosed
US-6399631-B1 3-AMIDO OR 3-SULFONAMIDO; EATING DISORDERS IN HUMANS, DOGS AND CATS PFIZER INC. 2002-06-04 US disclosed
EP-0411751-A1 Renin inhibitory peptides Beecham Group p.l.c. (GB) 1991-02-06 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080027036-A1 S1P receptor modulating compounds and use thereof S1PR1, S1PR5, S1PR2 HDAC3 4307/4885HDAC1 2524/4885HDAC8 2838/4885
US-20080064677-A9 S1P receptor modulating compounds and use thereof S1PR1, S1PR5, S1PR2 HDAC3 4307/4885HDAC1 2524/4885HDAC8 2838/4885
US-20110212940-A1 S1P Receptor Modulating Compounds and Use Thereof S1PR1, S1PR5, S1PR2 HDAC3 4307/4885HDAC1 2524/4885HDAC8 2838/4885
US-20110059945-A1 S1P Receptor Modulating Compounds and Use Thereof S1PR1, S1PR5, S1PR2 HDAC3 4307/4885HDAC1 2524/4885HDAC8 2838/4885
US-20070173487-A1 S1P receptor modulating compounds and use thereof S1PR1, S1PR5, S1PR2 HDAC3 4307/4885HDAC1 2524/4885HDAC8 2838/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.